|Title:||Circulating IGF system and treatment outcome in epithelial ovarian cancer||Authors:||Huang Y.-F.
|Issue Date:||2014||Journal Volume:||21||Journal Issue:||2||Start page/Pages:||217-229||Source:||Endocrine-Related Cancer||Abstract:||
Aggressive epithelial ovarian cancers (EOCs) frequently progress and become fatal, even when cytoreduction surgery plus platinum-based chemotherapy are performed. Thus, the early detection of high-risk subgroups is important in order to provide opportunities for better treatment outcomes, using alternative therapeutic strategies. This study aimed to explore the expression of circulating IGF system components and their relationship with treatment outcome in EOC. We included 228 patients with a median follow-up time of 44 months at two tertiary centers. There were 68 cancer deaths and 108 cases of cancer progression in the cohort. Preoperative serum levels of total IGF1, IGF2, IGF-binding protein 2 (IGFBP2), and IGFBP3 were analyzed using an ELISA and were then converted into an IGF1:IGFBP3 molar ratio. The risks of mortality and progression were estimated using Cox regression models in univariate and multivariate analyses. Our results showed that high IGF1, IGF2, and IGFBP3 levels were significantly associated with an early cancer stage, non-serous histology, and optimal cytoreduction. High IGFBP2 levels were associated with an advanced stage and serous histology. Overall and progression-free survival durations were significantly better among patients with high IGF1 (PZ0.003 and PZ0.001), IGF2 (PZ0.003 and PZ0.02), or IGFBP3 levels (PZ0.02 and PZ0.008). In multivariate analysis, serum IGFBP2 levels were significantly associated with increased risk of mortality (hazard ratioZ1.84, 95% CI: 1.07'3.18, PZ0.03), indicating that IGFBP2 could be used as an early predictor of EOCrelated mortality. The combination of elevated IGFBP2 and reduced IGF1 levels at diagnosis could further facilitate the identification of a patient subgroup with the worst prognosis. ? 2014 Society for Endocrinology.
|ISSN:||1351-0088||DOI:||10.1530/ERC-13-0274||SDG/Keyword:||somatomedin; somatomedin binding protein 2; somatomedin binding protein 3; adult; article; cancer adjuvant therapy; cancer growth; cancer mortality; cancer prognosis; cancer radiotherapy; cancer risk; cancer staging; cancer survival; controlled study; cytoreductive surgery; early cancer; enzyme linked immunosorbent assay; female; follow up; human; major clinical study; ovary carcinoma; progression free survival; proportional hazards model; treatment duration; treatment outcome; epithelial ovarian cancer; insulin-like growth factor; insulin-like growth factor-binding protein; prognosis; response to chemotherapy; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Preoperative Period; Prognosis; Treatment Outcome; Tumor Markers, Biological; Young Adult
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.